KRAS-targeting Pill Shows Promise Against Pancreatic Cancer
A new oral drug, daraxonrasib, targets the KRAS gene in pancreatic ductal adenocarcinoma, showing in early Phase 1/2 data a median overall survival around 13 months and tumor shrinkage in some patients, nearly doubling survival compared with standard chemotherapy; however, about 30% experience severe side effects, and questions about access and cost remain as full Phase 3 results near disclosure at ASCO.
